[go: up one dir, main page]

MX2022002433A - Análogos de compstatina y sus usos médicos. - Google Patents

Análogos de compstatina y sus usos médicos.

Info

Publication number
MX2022002433A
MX2022002433A MX2022002433A MX2022002433A MX2022002433A MX 2022002433 A MX2022002433 A MX 2022002433A MX 2022002433 A MX2022002433 A MX 2022002433A MX 2022002433 A MX2022002433 A MX 2022002433A MX 2022002433 A MX2022002433 A MX 2022002433A
Authority
MX
Mexico
Prior art keywords
compstatin
analogues
introduction
complement
inhibiting activity
Prior art date
Application number
MX2022002433A
Other languages
English (en)
Inventor
Anne Pernille Tofteng Shelton
Henrik Fischer Munch
Original Assignee
Zp Spv 3 K/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zp Spv 3 K/S filed Critical Zp Spv 3 K/S
Publication of MX2022002433A publication Critical patent/MX2022002433A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Psychology (AREA)
  • Hematology (AREA)

Abstract

Se describen análogos de compstatina que presentan una actividad de unión e inhibición del complemento mejorada en comparación con el péptido de compstatina de 13 aminoácidos (ICWQDWGHHRCT (C2-C12 cíclico)), en particular análogos de compstatina que además poseen propiedades fisicoquímicas útiles. Los análogos tienen un enlace de tipo tioéter en lugar de un enlace de tipo disulfuro entre las cadenas laterales de los residuos correspondientes a las cisteínas 2 y 12 de la compstatina, lo que puede aumentar su estabilidad. Los análogos también pueden tener un residuo de isoleucina en la posición 3 en lugar del residuo de valina de origen natural, lo que proporciona a los péptidos de compstatina una actividad mejorada de unión y de inhibición del complemento y también permite la introducción de otras modificaciones, por ejemplo, modificaciones que son capaces de aumentar la solubilidad tales como la introducción de aminoácidos cargados o polares en la posición 9 y/o la introducción de secuencias N- y/o C-terminales.
MX2022002433A 2019-08-27 2020-08-26 Análogos de compstatina y sus usos médicos. MX2022002433A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19193925 2019-08-27
EP20172189 2020-04-29
PCT/EP2020/073905 WO2021037942A1 (en) 2019-08-27 2020-08-26 Compstatin analogues and their medical uses

Publications (1)

Publication Number Publication Date
MX2022002433A true MX2022002433A (es) 2022-05-19

Family

ID=72178552

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022002433A MX2022002433A (es) 2019-08-27 2020-08-26 Análogos de compstatina y sus usos médicos.

Country Status (14)

Country Link
US (1) US20220306695A1 (es)
EP (2) EP4272751B1 (es)
JP (1) JP7711044B2 (es)
KR (1) KR20220066287A (es)
CN (1) CN114630836A (es)
AU (1) AU2020338688A1 (es)
BR (1) BR112022003760A2 (es)
CA (1) CA3148536A1 (es)
CO (1) CO2022003556A2 (es)
ES (1) ES3049784T3 (es)
IL (1) IL290858A (es)
MX (1) MX2022002433A (es)
TW (1) TW202128731A (es)
WO (1) WO2021037942A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7690287B2 (ja) * 2018-02-27 2025-06-10 セトペー エスペーベー ３ コマンディト セルスカブ コンプスタチン類似体及びその医療用途
CN116209671A (zh) * 2020-07-16 2023-06-02 西兰制药第三特殊目的公司 补体因子c3的抑制剂及其医学用途
KR20240118914A (ko) 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법
WO2023044290A1 (en) 2021-09-15 2023-03-23 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
WO2023048151A1 (ja) * 2021-09-22 2023-03-30 塩野義製薬株式会社 ウイルス増殖阻害活性を有する環状ペプチド
EP4622992A1 (en) * 2022-11-24 2025-10-01 Amyndas Pharmaceuticals US LLC Compstatin analogs for vector-based therapy

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000505068A (ja) 1996-03-13 2000-04-25 トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルベニア 補体活性化を阻害する新規ペプチド類
JP3149958B2 (ja) 1996-08-30 2001-03-26 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ―１誘導体
IL128829A (en) 1996-09-09 2005-08-31 Zealand Pharma As Solid phase sythesis of peptides with pre-sequences
AU4648197A (en) * 1997-09-17 1999-04-05 Burnham Institute, The Peptides and peptidomimetics for inhibiting complement activation
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
EP1956000B1 (en) 1999-03-17 2016-10-05 Novo Nordisk A/S Acylating agents useful for acylating peptides
JP4614222B2 (ja) 2002-09-20 2011-01-19 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア 改善された活性を有するコンプスタチン（Ｃｏｍｐｓｔａｔｉｎ）類似体
DK1951279T3 (en) 2005-10-08 2017-07-31 Apellis Pharmaceuticals Inc COMPSTATIN AND ANALOGUES THEREOF FOR EYE DISEASES
EP2377878B1 (en) 2005-11-28 2018-03-28 The Trustees Of The University Of Pennsylvania Potent compstatin analogs
WO2008153963A1 (en) 2007-06-08 2008-12-18 The Trustees Of The University Of Pennsylvania Structure of compstatin-c3 complex and use for rational drug design
CA2738930C (en) * 2008-09-30 2021-08-17 The Trustees Of The University Of Pennsylvania Method of inhibiting biomaterial-induced procoagulant activity using complement inhibitors
US20140113874A1 (en) 2010-09-23 2014-04-24 The Trustees Of The University Of Pennsylvania Modified Compstatin With Improved Stability And Binding Properties
EP2753636B1 (en) 2011-09-07 2019-10-23 The Trustees Of The University Of Pennsylvania Compstatin analogs with improved pharmacokinetic properties
US9512180B2 (en) 2012-12-19 2016-12-06 The Regents Of The University Of California Compstatin analogs
AR099569A1 (es) * 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
US20180057538A1 (en) * 2016-08-26 2018-03-01 The Regents Of The University Of California Potent and highly soluble pegylated compstatin peptides
JP7690287B2 (ja) * 2018-02-27 2025-06-10 セトペー エスペーベー ３ コマンディト セルスカブ コンプスタチン類似体及びその医療用途

Also Published As

Publication number Publication date
JP7711044B2 (ja) 2025-07-22
US20220306695A1 (en) 2022-09-29
CO2022003556A2 (es) 2022-05-20
BR112022003760A2 (pt) 2022-05-31
ES3049784T3 (en) 2025-12-18
JP2022545916A (ja) 2022-11-01
WO2021037942A1 (en) 2021-03-04
EP4272751B1 (en) 2025-09-24
EP4021921A1 (en) 2022-07-06
CA3148536A1 (en) 2021-03-04
EP4272751C0 (en) 2025-09-24
KR20220066287A (ko) 2022-05-24
AU2020338688A1 (en) 2022-03-24
TW202128731A (zh) 2021-08-01
EP4272751A2 (en) 2023-11-08
IL290858A (en) 2022-04-01
CN114630836A (zh) 2022-06-14
EP4272751A3 (en) 2024-02-14

Similar Documents

Publication Publication Date Title
MX2022002433A (es) Análogos de compstatina y sus usos médicos.
MX2020008902A (es) Analogos de compstatina y sus usos medicos.
EA200901459A1 (ru) Реконструированные поверхностно-активные вещества, имеющие улучшенные свойства
EA201100038A1 (ru) Коагонисты глюкагонового рецептора/glp-1-рецептора
EA201691111A1 (ru) Химерные белки фактора viii и их применение
DK2162462T3 (da) Cxc-chemokin-receptor-4 (cxcr4) antagonistisk polypeptid
RU2015101697A (ru) Аналоги глюкагона, обладающие активностью рецептора gip
MX377692B (es) Peptidos anti-inflamatorios y usos de los mismos.
RU2017101436A (ru) Mic-1 слитные белки и их применение
NZ628987A (en) Extended recombinant polypeptides and compositions comprising same
CY1123997T1 (el) Νεα μεταλλακτικη παραλλαγη αλβουμινης ανθρωπινου ορου
CL2011003121A1 (es) Proteína de fusión que comprende una secuencia de hormona de crecimiento (gh), ligada a un polipéptido recombinante extendido (xten) que comprende al menos 200 aminoácidos, carece de epítopes de células t y los residuos g, a, s, t, e y p suman más del 90%; ácido nucleico, vector y célula; método de producción; composición farmacéutica y uso.
MX2023000679A (es) Inhibidores del factor c3 del complemento y sus usos medicos.
NO20081654L (no) Stabiliserte GLP-1-analoger
BR112018013246A2 (pt) rótulo de peptídeo e proteína rotulada incluindo o mesmo
BR112022012057A2 (pt) Novos métodos de entrega celular
MX2019013801A (es) Compuestos de citocina inhibidora de macrofagos-1 (mic-1) y usos de estos.
MX2022007881A (es) Proteina f mutante del virus sincitial respiratorio (rsv) y usos de la misma.
PL415888A1 (pl) Sposób wytwarzania insuliny i jej pochodnych oraz peptyd hybrydowy stosowany w tym sposobie
MX2025001402A (es) Analogos de compstatina con mayor solubilidad y mejores propiedades farmacocineticas
MX2021001507A (es) Farmaco de diagnostico y metodo de diagnostico para la enfermedad de alzheimer.
WO2015110809A3 (en) Drug delivery system
ATE551353T1 (de) Protein mit fusogener wirkung, nukleinsäuresequenzen, die für dieses protein codieren und pharmazeutische zusammensetzungen, die dieses enthalten
NZ706202A (en) Peptide antagonists of the vasopressin-2 receptor
BR112022005782A2 (pt) Proteína galectina 9 estabilizada recombinante, vetor recombinante, transformante, composição farmacêutica para prevenção ou tratamento de uma doença óssea, alimento funcional de saúde para prevenção ou melhora de uma doença óssea, e, uso de uma proteína galectina 9 estabilizada recombinante